Drug Discovery World

SEPTEMBER 11, 2024

With the global economic burden of HF ($346 billion) expected to more than double by 2030, immediate action is required for early detection and intervention to reduce the disease burden and impact on patients, economies and society at large.

Pharma Companies 147

Pharma Companies Trials Disease Treatment 147

Drug Discovery World

APRIL 11, 2024

By 2030, it’s estimated that the global cost of COPD will rise to $4.8 trillion by 2030 1 , indicating a serious unmet need for new and improved therapeutics. Damage of this barrier is implicated in several chronic inflammatory diseases, including COPD.

Therapies 130

Therapies Clinical Trials Disease Trials 130

Drug Discovery World

APRIL 8, 2024

The company reported a reduction of Scope 1 and 2 global greenhouse gas (GHG) emissions by 37% over the last five years, targeting a 50% reduction by 2030. It achieved 92% renewable electricity usage globally, working toward the deployment of 100% renewable electricity across operations by 2030.

FDA 130

FDA Laboratories Government Science 130

Drug Discovery World

FEBRUARY 26, 2024

billion by 2030, with a growth rate of 10.2%. The global ADME toxicology testing market is predicted to generate a revenue of $19.21

Marketing 147

Marketing Drugs Pharmaceutical Companies Pharmaceuticals 147

Drug Discovery World

SEPTEMBER 13, 2024

The project, funded in part by LifeArc, has the potential to play a pivotal role in contributing towards the World Health Organization’s goal of a 60% survival rate by 2030 for all children with cancer globally.

Hospitals 147

Hospitals Clinical Research Treatment Research 147

The Pharma Data

MAY 1, 2023

In response, WHO, together with global partners and experts, took the leadership in developing a global strategy that sets forth a vision and roadmap to defeat meningitis by 2030. In November 2020, this global roadmap on meningitis was approved by the Seventy-Third World Health Assembly (resolution WHA73.9).

Treatment 40

Treatment Government Vaccine International 40

Drug Discovery World

JANUARY 18, 2024

million cases of cancer by 2030 1,2. Cancer immunotherapies, such as bispecific antibodies and CAR-T cell therapy, are rapidly moving into earlier lines of treatment in many tumour types, with these markets anticipated to grow to US$100bn+ (~35% CAGR) by 2030 3. In the US, the American Cancer Society estimates that there will be 24.6

Treatment 162

Treatment Clinical Trials Immune Response Therapies 162

Drug Discovery World

AUGUST 2, 2024

Obesity drug competition expected to intensify by 2030 Viking Therapeutics’ dual GLP-1/GIP receptor agonist VK2735 could become a direct competitor to Eli Lilly’s Mounjaro/Zepbound (tirzepatide), predicts data analytics company GlobalData. relative reduction in liver fat content (LFC), with up to 55.6%

Clinical Trials 130

Clinical Trials Drugs Treatment Disease 130

Drug Channels

APRIL 12, 2022

The econowonks at the Centers for Medicare & Medicaid Services (CMS) recently released the latest projections for U.S. spending on healthcare. See links below.) These data provide our first official look at post-pandemic U.S. healthcare spending. healthcare spending.

Pharmacy 98

Pharmacy Drugs Government Pharmaceuticals 98

Drug Channels

JULY 29, 2022

This week, I’m rerunning some popular posts while I prepare for today's live video webinar: Specialty Drugs Update: Trends, Controversies, and Outlook. Note that the forecasts below did not account for policy changes that could further reduce pharmaceuticals' share of U.S. healthcare spending.

Pharmacy 98

Pharmacy Drugs Government Pharmaceuticals 98

The Pharma Data

FEBRUARY 22, 2021

By 2030, Bayer aspires to reach gender parity on each individual management level. Moreover, Bayer strives to increase the proportion of people with disabilities in the workforce to more than 5 percent by 2030. In Germany, for example, it is currently 4.5

Compliance 52

Compliance Regulations Science Production 52

The Pharma Data

FEBRUARY 22, 2021

By 2030, Bayer aspires to reach gender parity on each individual management level. Moreover, Bayer strives to increase the proportion of people with disabilities in the workforce to more than 5 percent by 2030. In Germany, for example, it is currently 4.5

Compliance 40

Compliance Regulations 40

The Pharma Data

MAY 31, 2022

The initiative is supported by a multidisciplinary Steering Committee of patient advocacy leaders, healthcare professionals, biosimilar experts and industry leaders from around the world, with a mission to increase global adoption of biosimilar medicines by at least 30% in 30+ countries by 2030.

Biosimilars 52

Biosimilars Treatment Government Hospitals 52

Drug Discovery World

JULY 16, 2024

The World Health Organization has announced a goal of reducing the global burden of snakebite in half by 2030. Cobras kill thousands of people a year worldwide and many more are seriously maimed by necrosis caused by the venom, which can lead to amputation.

Science 130

Science Treatment Drugs Disease 130

BioPharma Drive: Drug Pricing

MARCH 1, 2024

Reeling from a difficult year financially, the pharma unveiled a new oncology division it says will produce eight billion-dollar medicines by 2030.

Drug Research 119

Drug Research Research Drugs 119

SCIENMAG: Medicine & Health

NOVEMBER 7, 2023

Brussels, 8 November 2023 – New international research on the economic burden of urinary incontinence reveals that the cost of continence care will reach an estimated €69.1 billion in 2023.

International 80

International Production Research 80

Drug Discovery World

AUGUST 18, 2023

billion to bring new antibiotics to market by 2030 through the AMR Action Fund. Advancing research, surveillance, and international collaboration on innovative solutions to combat AMR through a One Health approach is essential. The pharmaceutical industry has also stepped up support and invested £1.2

Laboratories 236

Laboratories Government International Hospitals 236

The Pharma Data

OCTOBER 25, 2021

It further evolves Boehringer Ingelheim’s commitments and significantly increases the company’s donation to appreciatively impacting health, societal and environmental issues, in alignment with the United Nations 2030 Sustainable Development Goals.

Vaccine 52

Vaccine Hospitals Disease Production 52

Drug Discovery World

JANUARY 4, 2023

Increasing collaborations and partnerships between market players are expected to contribute to significant growth in the antibodies market between 2022 and 2030, ResearchAndMarkets.com predicts.

Marketing 130

Marketing Drugs 130

Drug Discovery World

MAY 6, 2024

billion) Healthcare Innovation 2030 project, with ambitious plans to turn France into the European leader in health innovation by 2030. Since the launch of Healthcare Innovation 2030, investment has continued apace in the region. billion ($7.9

Drugs 147

Drugs Science Molecular Biology Clinical Trials 147

Drug Discovery World

JUNE 3, 2024

Identifying eligible patients through genomics Last year, the UK government signed an agreement with BioNTech to provide up to 10,000 patients with precision cancer immunotherapies by 2030.

Vaccine 147

Vaccine Trials Clinical Trials Hospitals 147

Drug Discovery World

DECEMBER 7, 2023

MND drug repurposing fund The fund is part of LifeArc’s multi-million pound Motor Neuron Disease Translational Challenge to make MND treatable by 2030 and ultimately find a cure. The Guiding Principles underpin a new £5 ($6.2)

Bioinformatics 130

Bioinformatics Clinical Trials Drugs Trials 130

Drug Discovery World

APRIL 14, 2023

Perhaps most significantly, Ghana accepted the R21/Matrix-M malaria vaccine for use in children, Moderna revealed that cancer vaccines could be ready by 2030, and a new treatment for long Covid fatigue could be available soon.

Vaccine 130

Vaccine Clinical Trials Drugs Pharmaceutical Companies 130

Drug Discovery World

AUGUST 8, 2023

Last month, the UK Chancellor and the Lord Mayor of London launched Mansion House Compact, which is an agreement by pension providers to allocate a minimum 5% to unlisted equities by 2030.

Science 246

Science Marketing Drugs 246

biobide

DECEMBER 1, 2023

Cannabis derivatives In 2022 the global legal cannabis market was valued at USD 22.1 This is forecasted to grow rapidly, with a growth rate of 25.5% A Key contributing factor to this significant growth prediction is the accelerating legalization of cannabis products and the growing acceptance of its use in the medical field and consumer goods.

Treatment 97

Treatment Production Marketing Research 97

Drug Discovery World

SEPTEMBER 15, 2023

It opens new perspectives for patients with difficult to treat cancers and the global market of targeted radiotherapies is expected to grow at a CAGR of 30% between 2023 and 2030. The collaboration will harness the capabilities of Orbit’s peptide display engine to identify peptide candidates specific to tumour-associated targets.

Therapies 130

Therapies Engineering DNA Marketing 130

thought leadership

JUNE 4, 2024

The HTAR will take effect in January 2025 for oncology and/or advanced therapy medicinal product (ATMP) therapies, with other therapies following a staggered implementation process, including orphan drugs in 2028 and all drugs in 2030.

Therapies 59

Therapies Regulations Production Marketing 59

Antidote

AUGUST 2, 2022

Not only does it impact many people today, but its prevalence is expected to double by 2030. Mitral valve regurgitation is a common kind of heart disease in the United States.

Disease 98

Disease 98

Drug Discovery World

MARCH 13, 2023

Partnering with ICON supports our 2030 strategy as it will help us to bring innovative treatments to patients faster while also supporting a more sustainable business through scalability and flexibility,” said Jörg Möller, Executive Vice President and head of Global R&D at LEO Pharma.

Trials 130

Trials Clinical Trials Laboratories Clinical Development 130

Drug Discovery World

SEPTEMBER 5, 2022

In fact, the government is targeting over $50 billion in exports by 2030 and many international companies are accelerating efforts to deepen local supply networks. South Korea recovered from the pandemic earlier than many other Asian countries and reported rapid growth in its contract manufacturing industry in the last two years. .

International 130

International Government Marketing Drugs 130

Agency IQ

FEBRUARY 23, 2024

NANCY SKINNER has updated a bill she introduced in early January 2024 to ban the sale of intentionally added PFAS in the state after 2030. BY WALKER LIVINGSTON, ESQ California state Sen. Although the bill may receive state support, the actual implementation of the ban, if passed, would be a herculean task.

59

59

Drug Discovery World

JULY 14, 2023

The MOU reflects Lifera’s strategic mission to increase national resilience and grow the biopharma sector by enabling technology transfer, the creation of a skilled biopharmaceutical workforce and advancing Saudi Arabia’s Vision 2030.

Vaccine 130

Vaccine International Pharmaceuticals Marketing 130

Drug Discovery World

MAY 31, 2024

billion by 2030, according to a market research report by Market Research Future. ” The US schizophrenia market is projected to grow to $8.06

Licensing 147

Licensing Licensing FDA Approval Drugs 147

Drug Discovery World

JANUARY 19, 2023

Worryingly, according to the United Nations, national climate plans for parties to the Paris Agreement would bring us back to 2010 emission levels, leading to a rise of around 11% in greenhouse gases by 2030.

Pharmaceuticals 130

Pharmaceuticals Pharmaceutical Companies Clinical Trials Government 130

Agency IQ

MAY 10, 2024

BY RAYAN BHARGAVA, MSC | MAY 9, 2024 11:03 PM CDT Regulatory background Until recently, the EU had plans to halve pesticide reduction by 2030. In late October 2023, the French government announced yet another version: Ecophyto 2030. However, intense farmer protests led the French government to pause Ecophyto 2030 indefinitely. [

Government 40

Government Regulations Production Marketing 40

Drug Discovery World

FEBRUARY 28, 2023

billion by 2030. Age-related diseases such as arthritis, sarcopenia and Alzheimer’s Disease are among the leading causes of disability and mortality across the developed world, and a major burden on health funding. Globally, the anti-ageing therapeutics market is expected to reach $2.01 Anti-ageing science therefore has huge value.

Small Molecule 130

Small Molecule Disease Science Treatment 130

Drug Discovery World

DECEMBER 12, 2023

2023-2030 for diabetic retinopathy alone), the demand for a topical therapy is high. Coupled with a large and growing market (US$8.3 billion, CAGR 6.4% Exonate is building on its expertise in alternative splicing to develop medicines to treat end organ disease caused by poor diabetic control.

Small Molecule 130

Small Molecule Trials Pharmacokinetics Treatment 130